Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

S.C.P.C Investor Presentation 2021

Nov 17, 2021

51900_rns_2021-11-17_accd5d8c-985f-4d47-b8c7-55b550fb8541.pdf

Investor Presentation

Open in viewer

Opens in your device viewer

==> picture [508 x 268] intentionally omitted <==

Standard Chem & Pharm CO., LTD. Stock Symbol:1720

2021 Investor Conference 11/18/2021

==> picture [320 x 85] intentionally omitted <==

==> picture [98 x 91] intentionally omitted <==

Agenda

Introduction of Standard Group

2021 Q1-Q3 Operating Results

Future Operation Strategy

Corporate Social Responsibility (CSR)

1

© 2021 SCPC, Ltd

Reminder

==> picture [98 x 91] intentionally omitted <==

Please set your microphone to mute during the meeting, and only turn on the microphone when you speak.

  • Procedure:

  • Opening

  • Report procedure(Please do not hesitate to ask questions when we finish our report )

  • Introduction of Standard Group & 2021 Quarterly Operating Results: By CFO

  • Future Operation Strategy & Corporate Social Responsibility (CSR)：By President

  • Q&A

  • Please use the raise hand feature when asking questions and wait to be called on. We welcome all opinions.

2

© 2021 SCPC, Ltd

免責聲明 Safe Harbor Notice

==> picture [98 x 91] intentionally omitted <==

本次簡報與討論包含特定預測性的說明，而其內容有關於營運結果、財務狀況，以及對未來事 件的預期。因為此等前瞻性說明是有關於未來事件，而且取決於未來發生時的環境因素，所以必 然含有風險與不確定性。

本公司將不負擔公開更新或修改這些預測性的說明之義務，無論是出現新資訊、未來發生任何 事件，或其他情況。實際結果可能與此等預測性說明推測的內容有重大差異。

In these presentations and discussions, there are certain forward looking statements regarding the results of operation, financial condition and current expectation about future events. As forward-looking statements relate to events and depend on circumstances in the future, they involve risk and uncertainty.

We do not undertake any obligation to publicly revise or update any forward looking statements for availability of new information, future events or otherwise. Real result probably differ substantially from those expected in these forward-looking statements.

3

© 2021 SCPC, Ltd

==> picture [98 x 91] intentionally omitted <==

Agenda

Introduction of Standard Group

2021 Q1-Q3 Operating Results

Future Operation StrategyCorporate Social Responsibility (CSR)

4

© 2021 SCPC, Ltd

==> picture [919 x 483] intentionally omitted <==

----- Start of picture text -----

SCP and Related/Affiliated Companies
Upstream Manufacture Downstream
Syn-Tech (1982; 2005 SCP(1967;
Taiwan Biosim(2017)
Over-The-Counter (OTC) ) 1995 listed stock)
Western
medicine
Your Chance
Syngen(1999; 2016 OTC ) Souriree(1997)
(2013 Re-investment)
Multipower
Syngen(1999)
(2012 Re-investment)
Healthcare
nutrition
Sun-you(1994) Advpharma (1999)
Medical-
Syngen (1999)
devices
Q
Inforight(2000)
Gene chip Advpharma (1999) Software/Hardware
service support
5
----- End of picture text -----

==> picture [127 x 17] intentionally omitted <==

----- Start of picture text -----

© 2021 SCPC, Ltd
----- End of picture text -----

International Accreditation

==> picture [698 x 46] intentionally omitted <==

----- Start of picture text -----

1998 2000 2008 2009 2010 2017 2021
----- End of picture text -----

==> picture [47 x 50] intentionally omitted <==

==> picture [32 x 42] intentionally omitted <==

The first TW pharmaceutical company to be ISO9001 certified

==> picture [56 x 35] intentionally omitted <==

==> picture [51 x 28] intentionally omitted <==

The first TW company to pass US FDA inspection in 2000

SCP passed subsequent US FDA cGMP inspections without 483

==> picture [31 x 42] intentionally omitted <==

SCP received JP PMDA’s

FDF Plant and API Plant passed PMDA GMP Audit in 2018

==> picture [56 x 34] intentionally omitted <==

“Certificate of Foreign Drug Manufacturer” in 2008

==> picture [64 x 41] intentionally omitted <==

2009

==> picture [54 x 37] intentionally omitted <==

SCP’s API plant passed AU TGA inspection

==> picture [50 x 39] intentionally omitted <==

2010 SCP passed TW PIC/S GMP inspection 2012 SCP is certified GDP by the T-FDA 2012 SCP passed K-FDA inspection

==> picture [54 x 40] intentionally omitted <==

==> picture [54 x 38] intentionally omitted <==

==> picture [98 x 91] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 63] intentionally omitted <==

==> picture [67 x 72] intentionally omitted <==

----- Start of picture text -----

Q
----- End of picture text -----

==> picture [50 x 49] intentionally omitted <==

----- Start of picture text -----

4 6
----- End of picture text -----

© 2021 SCPC, Ltd

==> picture [98 x 91] intentionally omitted <==

Agenda

Introduction of Standard Group2021 Q1-Q3 Operating Results

Future Operation StrategyCorporate Social Responsibility (CSR)

7

© 2021 SCPC, Ltd

54 Years of Continuous Profit

Profit Cash Dividends Stock Dividends EPS 600,000 500,000

400,000 2.09[2.15 ] 2.09 2.03[2.09 ][2.11 ] 1.95 1.90 1.77[1.81 1.88 ] 1.61[1.73 ] 300,000 1.35[1.47 ] 200,000 1.20[1.50 1.25 ] 1.20 1.60 0.50[1.00 1.20 ] 1.00 1.50 1.50 1.60 1.50 1.50 2.50 100,000 0.70 0.30 0.30 0

==> picture [101 x 76] intentionally omitted <==

2.93[2.99 ]

1.80

==> picture [61 x 47] intentionally omitted <==

3.50 3.00

2.50 2.00 1.50 1.00 0.50 0.00

==> picture [98 x 91] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 63] intentionally omitted <==

Q

8

© 2021 SCPC, Ltd

Consolidated Income Statement

Items 2021 Q1-Q3 2020 Q1-Q3 Diff. Annual
changes(%)








(Unless otherwise specified, expressed in
thousands of New Taiwan Dollars)
Operatingrevenue 3,371,013
3,187,827
183,186
6%
Grossprofit 1,526,457
1,413,946
70,675
8%
Grossprofit margin 45.28%
44.35%		 +0.9pct
Operatingexpenses 892,428
888,657
3,771
0%
Operating profit 634,029
525,289
108,740
21%
Non-operating income and
expenses		 113,148
33,916
79,232
234%

Profit before income tax		 747,177
559,205
187,972
34%
Profit for theyear 625,114
445,656
179,458
40%
Profit attributable to owners of the
parent		 533,781
364,062
169,719
47%

EPS(NTD)		 2.99
2.04
0.95
47%
2021 SCPC, Ltd

==> picture [98 x 91] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 63] intentionally omitted <==

Q

9

© 2021 SCPC, Ltd

Comparison of Quarterly Revenue of Past 5 Years (Consolidated)


 2021 SCPC, Ltd
10
Comparison of Quarterly Revenue of Past 5 Years
(Consolidated)
0
200,000
400,000
600,000
800,000
1,000,000
1,200,000
2016
2017
2018
2019
2020
2021
Expressed in thousands of NTD
Q
Q1
Q2
Q3
Q4
Total
Growth
(%)
2016
859,024
940,238
919,663
954,876
3,673,801
2017
909,933
976,177
1,056,753
905,821
3,848,684
+5%
2018
763,261
897,693
913,353
998,786
3,573,093
-7%
2019
846,177
1,010,837
1,048,886
1,031,229
3,937,129
+10%
2020
1,034,417
1,108,059
1,045,351
1,117,573
4,305,400
+9%
2021
1,101,113
1,149,060
1,120,840
3,371,013
+6%
16 17 18 19 20 21
16 17 18 19 20 21
16 17 18 19 20 21
16 17 18 19 20		 2021 SCPC, Ltd
10
Comparison of Quarterly Revenue of Past 5 Years
(Consolidated)
0
200,000
400,000
600,000
800,000
1,000,000
1,200,000
2016
2017
2018
2019
2020
2021
Expressed in thousands of NTD
Q
Q1
Q2
Q3
Q4
Total
Growth
(%)
2016
859,024
940,238
919,663
954,876
3,673,801
2017
909,933
976,177
1,056,753
905,821
3,848,684
+5%
2018
763,261
897,693
913,353
998,786
3,573,093
-7%
2019
846,177
1,010,837
1,048,886
1,031,229
3,937,129
+10%
2020
1,034,417
1,108,059
1,045,351
1,117,573
4,305,400
+9%
2021
1,101,113
1,149,060
1,120,840
3,371,013
+6%
16 17 18 19 20 21
16 17 18 19 20 21
16 17 18 19 20 21
16 17 18 19 20		 2021 SCPC, Ltd
10
Comparison of Quarterly Revenue of Past 5 Years
(Consolidated)
0
200,000
400,000
600,000
800,000
1,000,000
1,200,000
2016
2017
2018
2019
2020
2021
Expressed in thousands of NTD
Q
Q1
Q2
Q3
Q4
Total
Growth
(%)
2016
859,024
940,238
919,663
954,876
3,673,801
2017
909,933
976,177
1,056,753
905,821
3,848,684
+5%
2018
763,261
897,693
913,353
998,786
3,573,093
-7%
2019
846,177
1,010,837
1,048,886
1,031,229
3,937,129
+10%
2020
1,034,417
1,108,059
1,045,351
1,117,573
4,305,400
+9%
2021
1,101,113
1,149,060
1,120,840
3,371,013
+6%
16 17 18 19 20 21
16 17 18 19 20 21
16 17 18 19 20 21
16 17 18 19 20		 2021 SCPC, Ltd
10
Comparison of Quarterly Revenue of Past 5 Years
(Consolidated)
0
200,000
400,000
600,000
800,000
1,000,000
1,200,000
2016
2017
2018
2019
2020
2021
Expressed in thousands of NTD
Q
Q1
Q2
Q3
Q4
Total
Growth
(%)
2016
859,024
940,238
919,663
954,876
3,673,801
2017
909,933
976,177
1,056,753
905,821
3,848,684
+5%
2018
763,261
897,693
913,353
998,786
3,573,093
-7%
2019
846,177
1,010,837
1,048,886
1,031,229
3,937,129
+10%
2020
1,034,417
1,108,059
1,045,351
1,117,573
4,305,400
+9%
2021
1,101,113
1,149,060
1,120,840
3,371,013
+6%
16 17 18 19 20 21
16 17 18 19 20 21
16 17 18 19 20 21
16 17 18 19 20		 2021 SCPC, Ltd
10
Comparison of Quarterly Revenue of Past 5 Years
(Consolidated)
0
200,000
400,000
600,000
800,000
1,000,000
1,200,000
2016
2017
2018
2019
2020
2021
Expressed in thousands of NTD
Q
Q1
Q2
Q3
Q4
Total
Growth
(%)
2016
859,024
940,238
919,663
954,876
3,673,801
2017
909,933
976,177
1,056,753
905,821
3,848,684
+5%
2018
763,261
897,693
913,353
998,786
3,573,093
-7%
2019
846,177
1,010,837
1,048,886
1,031,229
3,937,129
+10%
2020
1,034,417
1,108,059
1,045,351
1,117,573
4,305,400
+9%
2021
1,101,113
1,149,060
1,120,840
3,371,013
+6%
16 17 18 19 20 21
16 17 18 19 20 21
16 17 18 19 20 21
16 17 18 19 20		 2021 SCPC, Ltd
10
Comparison of Quarterly Revenue of Past 5 Years
(Consolidated)
0
200,000
400,000
600,000
800,000
1,000,000
1,200,000
2016
2017
2018
2019
2020
2021
Expressed in thousands of NTD
Q
Q1
Q2
Q3
Q4
Total
Growth
(%)
2016
859,024
940,238
919,663
954,876
3,673,801
2017
909,933
976,177
1,056,753
905,821
3,848,684
+5%
2018
763,261
897,693
913,353
998,786
3,573,093
-7%
2019
846,177
1,010,837
1,048,886
1,031,229
3,937,129
+10%
2020
1,034,417
1,108,059
1,045,351
1,117,573
4,305,400
+9%
2021
1,101,113
1,149,060
1,120,840
3,371,013
+6%
16 17 18 19 20 21
16 17 18 19 20 21
16 17 18 19 20 21
16 17 18 19 20		 2021 SCPC, Ltd
10
Comparison of Quarterly Revenue of Past 5 Years
(Consolidated)
0
200,000
400,000
600,000
800,000
1,000,000
1,200,000
2016
2017
2018
2019
2020
2021
Expressed in thousands of NTD
Q
Q1
Q2
Q3
Q4
Total
Growth
(%)
2016
859,024
940,238
919,663
954,876
3,673,801
2017
909,933
976,177
1,056,753
905,821
3,848,684
+5%
2018
763,261
897,693
913,353
998,786
3,573,093
-7%
2019
846,177
1,010,837
1,048,886
1,031,229
3,937,129
+10%
2020
1,034,417
1,108,059
1,045,351
1,117,573
4,305,400
+9%
2021
1,101,113
1,149,060
1,120,840
3,371,013
+6%
16 17 18 19 20 21
16 17 18 19 20 21
16 17 18 19 20 21
16 17 18 19 20
Q1 Q2 Q3 Q4 Total Growth
(%)
2016 859,024
940,238
919,663
954,876
3,673,801
2017 909,933
976,177
1,056,753
905,821
3,848,684
+5%
2018 763,261
897,693
913,353
998,786
3,573,093
-7%
2019 846,177
1,010,837
1,048,886
1,031,229
3,937,129
+10%
2020 1,034,417
1,108,059
1,045,351
1,117,573
4,305,400
+9%
2021 1,101,113
1,149,060
1,120,840		 3,371,013
+6%
2021 SCPC, Ltd

© 2021 SCPC, Ltd

Global Revenue - Ratio of Past 5 Years International sales (Consolidated)

International Domestic

==> picture [629 x 251] intentionally omitted <==

----- Start of picture text -----

19.2% 80.8%
17.9% 82.1%
17.2% 82.8%
19.2% 80.8%
19.4% 80.6%
17.5% 82.5%
----- End of picture text -----

2021Q1-Q3 2020 2019 2018 2017 2016

Expressed in thousands of NTD **2021Q1-Q3 ** 2020 2019 2018 2017 2016
Export revenue 646,019 768,863 678,464 686,077 745,705 644,528
Total operating revenue 3,371,013 4,305,400 3,937,129 3,573,093 3,848,684 3,673,801

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 63] intentionally omitted <==

Q

11

© 2021 SCPC, Ltd

Global Revenue Ratio Comparison-Export distribution (Consolidated)

50,000
100,000
150,000
200,000
250,000
300,000
2021 Q1-Q3 Export sales increased by 78million(13.8%)
2021Q1-Q3
2020Q1-Q		 50,000
100,000
150,000
200,000
250,000
300,000
2021 Q1-Q3 Export sales increased by 78million(13.8%)
2021Q1-Q3
2020Q1-Q		 50,000
100,000
150,000
200,000
250,000
300,000
2021 Q1-Q3 Export sales increased by 78million(13.8%)
2021Q1-Q3
2020Q1-Q		 50,000
100,000
150,000
200,000
250,000
300,000
2021 Q1-Q3 Export sales increased by 78million(13.8%)
2021Q1-Q3
2020Q1-Q		 50,000
100,000
150,000
200,000
250,000
300,000
2021 Q1-Q3 Export sales increased by 78million(13.8%)
2021Q1-Q3
2020Q1-Q		 50,000
100,000
150,000
200,000
250,000
300,000
2021 Q1-Q3 Export sales increased by 78million(13.8%)
2021Q1-Q3
2020Q1-Q		 50,000
100,000
150,000
200,000
250,000
300,000
2021 Q1-Q3 Export sales increased by 78million(13.8%)
2021Q1-Q3
2020Q1-Q		 50,000
100,000
150,000
200,000
250,000
300,000
2021 Q1-Q3 Export sales increased by 78million(13.8%)
2021Q1-Q3
2020Q1-Q		 50,000
100,000
150,000
200,000
250,000
300,000
2021 Q1-Q3 Export sales increased by 78million(13.8%)
2021Q1-Q3
2020Q1-Q		 50,000
100,000
150,000
200,000
250,000
300,000
2021 Q1-Q3 Export sales increased by 78million(13.8%)
2021Q1-Q3
2020Q1-Q
0 China Southeast
Asia		 Other Asia Europe Japan Other
Americas		 USA Africa Others
2021 Q1-Q3 280,482 158,577 97,694 27,097 25,061 23,493 18,681 14,647 287
2020 Q1-Q3 152,367 178,485 85,427 29,718 45,616 33,483 23,229 19,072 149
21 SCPC, Ltd

2021Q1-Q3 2020Q1-Q3

==> picture [64 x 65] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 63] intentionally omitted <==

==> picture [67 x 72] intentionally omitted <==

----- Start of picture text -----

Q
----- End of picture text -----

12

© 2021 SCPC, Ltd

Consolidated Balance Sheet

Items 2021/9/30 2021/9/30 2020/9/30 2020/9/30 Diff. Annual
changes(%)










(Expressed in thousands of NTD) Amount % Amount %
Cash and cash equivalents 1,325,452
18%
847,614
12%
477,838
56%
Accounts receivable 1,073,504
14%
960,603
14%
112,901
12%
Inventories 968,244
13%
909,504
13%
58,740
6%
Investments 1,173,117
16%
709,160
10%
463,957
65%
Property,plant and equipment 2,074,708
28%
2,294,229
34%
(219,521)
(10%)
Others 795,380
11%
1,113,357
16%
(317,977)
(29%)
Total Assets 7,410,405 100%
6,834,467		 100%
121,443
2%
Current Liabilities 1,740,975
23%
1,615,269
24%
125,706
8%
Non-current Liabilities 526,817
7%
492,950
7%
33,867
7%
Total liabilities 2,267,792
31%
2,108,219
31%
159,573
8%
Total shareholder’s equity 5,142,613
69%
4,726,248
69%
(38,130)
(1%)
Debt Ratio(Abilities/Assets) 31% 31%
2021 SCPC, Ltd

==> picture [98 x 91] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 63] intentionally omitted <==

Q

13

© 2021 SCPC, Ltd

Consolidated Cash Flows

Items 2021 Q1-Q3 2020 Q1-Q3


(Expressed in thousands of NTD)
Cash at beginning ofyear 1,036,183
1,471,902
Cash flows from operatingactivities 557,366
518,989
Acquisition ofproperty, plant and equipment (97,533) (268,885)
Cash dividends (321,653) (268,044)
Short-term borrowings (28,490) (39,500)
Investment and others 179,579
(566,848)
Cash at end ofyear 1,325,452
847,614
Free cash flow*
(Cash flows from operating activities-Acquisition of property, plant and equipment)		 459,833
250,104

==> picture [98 x 91] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 63] intentionally omitted <==

Q

==> picture [64 x 65] intentionally omitted <==

14

© 2021 SCPC, Ltd

==> picture [98 x 91] intentionally omitted <==

Agenda

Introduction of Standard Group2021 Q1-Q3 Operating Results

Future Operation Strategy

Corporate Social Responsibility (CSR)

15

© 2021 SCPC, Ltd

Q

Future Milestone

==> picture [290 x 122] intentionally omitted <==

==> picture [97 x 123] intentionally omitted <==

From Taiwan to International From Generics to Better than Generics (BTG)

==> picture [356 x 123] intentionally omitted <==

==> picture [98 x 91] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 63] intentionally omitted <==

==> picture [533 x 39] intentionally omitted <==

16

© 2021 SCP, Ltd

SCP – Major International Businesses of the Past 2 Years

==> picture [59 x 58] intentionally omitted <==

==> picture [58 x 58] intentionally omitted <==

==> picture [73 x 58] intentionally omitted <==

Japan

China

Taiwan

• Bronchiolitis drug, non​steroid anti-inflammatory drugs are persistently delivery.

• • Prompt delivery of drugs Continues export of antibiotic during COVID-19 due to injection. well-managed production • Generic Quality Consistency and sales coordination. Evaluation(GQCE) ： 3 cases • SCPs cumulated sales were closed; 5 ongoing and profit have hit a applications. historic high even after • Self-developed generic drug: deducting one-time in submission. revenue.

==> picture [98 x 91] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [31 x 27] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 63] intentionally omitted <==

Q

==> picture [43 x 39] intentionally omitted <==

17

© 2021 SCPC, Ltd

Revenue Growth Strate - China gy

==> picture [80 x 81] intentionally omitted <==

Competitiveness

==> picture [77 x 61] intentionally omitted <==

  •  SCP has successful experience with U.S. and Japan regulatory dossiers  SCP to continue to specialize expertise in BE design and execution

NMPA review of importation

Medium-term targets

  • NMPA Consistency Evaluation

  • 8 contracts signed, 3 cases were closed, and 5 ongoing cases

 Self-developed products submission

  • Enhance profit sharing revenue

Cooperation

Strategy

 Tech-transfer

  • Emphasize export and tech transfer simultaneously.

  • Increase the number of cooperative projects and pharmaceutical companies

 License cooperation

  • Co-development

  • Profit-sharing Partnerships

==> picture [98 x 91] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 63] intentionally omitted <==

Q

==> picture [50 x 49] intentionally omitted <==

----- Start of picture text -----

18
----- End of picture text -----

© 2021 SCPC, Ltd

The Current Status of China- Market Trends

China Pharmaceutical National Healthcare Security Brand Drugs Firms Administration Transfer from centralized Stay at market trends of API and Expend centralized procurement to external market focus on high techniques threshold procurement products • • Brand drug prices are high and so Centralized procurement volume • As centralized procurement status, only minority brand drug can win the accounted for about 80% of total the majority firms tend to develop bid in centralized procurement. market volume. their own API to decrease the price. • • Brand drug will not decrease the After 6 centralized procurements, Lower gross margin, but prices overly even they don’t win the 600 products were included. compensated with high sale volume. • bid, they still have high market share The products will expend to orphan • Focus on high techniques threshold and profit. drug, shortage drug, Bio-similar and products with fewer competitor drugs, and Chinese medicine.

==> picture [98 x 91] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 63] intentionally omitted <==

==> picture [67 x 72] intentionally omitted <==

----- Start of picture text -----

Q
----- End of picture text -----

==> picture [50 x 49] intentionally omitted <==

----- Start of picture text -----

19
----- End of picture text -----

© 2021 SCPC, Ltd

Revenue Growth Strategy - Japan

==> picture [76 x 72] intentionally omitted <==

Collaboration Model Raw Material Strategy

 Strategic alliance with API manufacturer.

  • CDMO

  • Japan marketing partner

  • • License Holder

 API Vertical Integration with Syn-Tech.

==> picture [78 x 74] intentionally omitted <==

Current State

On Going

 Obtained marketing licenses for Montelukast (Asthma) and Celecoxib (Anti-inflammatory)

  • New business is continuing

  • development.

==> picture [98 x 91] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 63] intentionally omitted <==

==> picture [67 x 72] intentionally omitted <==

----- Start of picture text -----

Q
----- End of picture text -----

==> picture [50 x 49] intentionally omitted <==

----- Start of picture text -----

20
----- End of picture text -----

© 2021 SCPC, Ltd

Revenue Growth Strate – U.S.A. gy

==> picture [174 x 125] intentionally omitted <==

U.S.A. Market

  • Largest Rx Market

  • Characterized by lengthy review

  • timelines and costly compilation and filing work

  • SCP’s long term goals

Current Status

Strategy

  • Strategic alliance with API manufacturer.

  • Export of diabetic and amyotrophic

  • lateral sclerosis(ALS) drugs treatment

  • API Vertical Integration with Syn-Tech.

  • P4 approved, pending

  • for patent expiration

==> picture [98 x 91] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 63] intentionally omitted <==

==> picture [67 x 72] intentionally omitted <==

----- Start of picture text -----

Q
----- End of picture text -----

==> picture [50 x 49] intentionally omitted <==

----- Start of picture text -----

21
----- End of picture text -----

© 2021 SCPC, Ltd

USA – 100 Da Su l Chain Re ort y pp y p

  • 4 Critical Supply Chain:

==> picture [30 x 363] intentionally omitted <==

----- Start of picture text -----

Day Adm. Order Review
----- End of picture text -----

  • Semiconductor

  • Large Capacity Batteries

  • Critical Minerals and Materials

  • Pharmaceuticals & Active Pharmaceutical Ingredient

  • Review the degree of dependence of critical products on foreign countries

  • Improve supply chain diversification

  • Avoid over-reliance of certain product on other countries (eg. China, India)

  • Promoting international cooperation and partnering with allies

==> picture [98 x 91] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 63] intentionally omitted <==

Q

==> picture [50 x 49] intentionally omitted <==

----- Start of picture text -----

22
----- End of picture text -----

© 2021 SCP, Ltd

SCP’s Alliance with EASYWELL BIOMEDICALS

==> picture [485 x 317] intentionally omitted <==

EASYWELL’s US production base: Tulex Pharmaceuticals

  • Located in New Jersey

  • Obtained steady order from US department of Defense

==> picture [98 x 91] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 63] intentionally omitted <==

Q

23

© 2021 SCP, Ltd

Future Operation Strategy

Future From Taiwan to International From Generics to BTG

2022 USA、Japan

2021 China

Core techniques and professional Global marketing 核心技術 skills to expend & 專業 海外市場操作 practices global sales turnover 借力使力

Increasing oversea Marketing revenue 增加海 外比例

  • Enhance oversea sales’

Foundation improvementCreate turnover rapidlyPay attention to different countries marketing knowledge and business roleSeeking medium and long-term stability partnership cooperation

Mature R&D techniques to create turnover

resources

  • Hire international

talents

==> picture [98 x 91] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 63] intentionally omitted <==

Q

==> picture [50 x 49] intentionally omitted <==

----- Start of picture text -----

24
----- End of picture text -----

© 2021 SCPC, Ltd

Awarded as Outstanding Bio Company of the ear 2021 b IBMI y y

  • Since 2014, SCP is recognized again as an Outstanding Bio-Company for year 2021 by IBMI

==> picture [489 x 307] intentionally omitted <==

==> picture [98 x 91] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 63] intentionally omitted <==

==> picture [67 x 72] intentionally omitted <==

----- Start of picture text -----

Q
----- End of picture text -----

==> picture [50 x 49] intentionally omitted <==

----- Start of picture text -----

25
----- End of picture text -----

© 2021 SCP, Ltd

The Greatest Honor with Drug Technology Development Award in 2021

==> picture [247 x 371] intentionally omitted <==

  • Antihypertensive drug- Co-Midis Tablet is honored with the only gold award as the greatest honor in manufacturing technology category.

  • It is a compound long-acting medicine with minimum side effect. A steady control of blood pressure can be achieved by only taking one tablet a day.

  • After 2 year of patent review, the patent of “immediaterelease medicinal composition” was obtain on September 2021.

  • After 2 years of Co-Midis Table’s launch on May 2019, the sale is expected to exceed NT100 million per year.

==> picture [223 x 153] intentionally omitted <==

==> picture [98 x 91] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 63] intentionally omitted <==

==> picture [67 x 72] intentionally omitted <==

----- Start of picture text -----

Q
----- End of picture text -----

26

© 2021 SCP, Ltd

==> picture [98 x 91] intentionally omitted <==

Agenda

Introduction of Standard Group2021 Q1-Q3 Operating Results

Further Operation StrategyCorporate Social Responsibility (CSR)

27

© 2021 SCPC, Ltd

Fan Dao Nan Foundation

Fan Dao Nan Foundation

==> picture [184 x 136] intentionally omitted <==

  • Established in 1987

  • Endowment Fund: NT$196 Million

 Annual Budget: NT$12 Million

==> picture [184 x 135] intentionally omitted <==

Principal Activities

  • Non-profit education

 Cultural and educational

 Sponsor R&D and Innovation

development activities

  • Scholarships and Talent Cultivation

==> picture [186 x 137] intentionally omitted <==

Rewards and Honors Received

 2011: Special Recognition Award – Dept. of Education

 2012: Tainan City Govt. Grant for Scholarship Program  2013: National Special Selection Award for After-School Program – Dept. of Education

==> picture [98 x 91] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 63] intentionally omitted <==

Q

==> picture [50 x 49] intentionally omitted <==

----- Start of picture text -----

28
----- End of picture text -----

© 2021 SCPC, Ltd

Cor orate Social Res onsibilit in 2020 p p y

==> picture [51 x 52] intentionally omitted <==

==> picture [51 x 52] intentionally omitted <==

==> picture [51 x 51] intentionally omitted <==

Scholarships

Sunflower Wednesdays

Hope After-school Class

  •  University (related fields)::3university/4 students

˙Weekday afternoons

˙Every Wednesday afternoons

==> picture [98 x 91] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

High school :7schools/ totaled 113 students

Middle school:61schools/totaled 807 students

  •  Elementary school :237schools/totaled 2,760 students

Total scholarship NTD 6.34 MM

==> picture [52 x 51] intentionally omitted <==

Other Sponsorships

 Sponsorship to 11 non-forprofit organization for cultural and educational advancement

Grant Total- NTD 560KK

， ˙22 schools 1,780students

Total scholarship NTD 1.81MM

==> picture [52 x 51] intentionally omitted <==

Meal-Assistance

 In 2020, provided 4,553 meals to students during winter and summer vacation. Assisted Total- NTD270KK

==> picture [32 x 20] intentionally omitted <==

==> picture [19 x 19] intentionally omitted <==

==> picture [44 x 12] intentionally omitted <==

， ˙4 Schools 243student

Total scholarship NTD 400KK

==> picture [52 x 51] intentionally omitted <==

==> picture [51 x 52] intentionally omitted <==

Charity

SCP Children’s Drawing

Competition

SCP National Table Tennis Competition*

Prize Total – NT$250KK

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 63] intentionally omitted <==

==> picture [67 x 72] intentionally omitted <==

----- Start of picture text -----

Q
----- End of picture text -----

29

© 2021 SCPC, Ltd

The First Senior Gym in Taiwan – Athletic Training and Health Center

==> picture [162 x 217] intentionally omitted <==

From Jan. to Sep. of 2021,

  • The number of users is accumulated 79,245 user time.

  • 5 healthy lectures were conducted that provide disease and healthcare knowledge.

==> picture [98 x 91] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 63] intentionally omitted <==

==> picture [67 x 72] intentionally omitted <==

30

© 2021 SCP, Ltd

Free Bone Mass Measurement and Community Health Seminar

==> picture [213 x 169] intentionally omitted <==

From Jan. to Sep. of 2021,

  • 3 sessions of free bone mass measurement activity have been held and 230 people were measured.

==> picture [98 x 91] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 64] intentionally omitted <==

==> picture [64 x 63] intentionally omitted <==

Q

  • 2 sessions of community health lectures have been held, with a total of 70 participants.

© 2021 SCP, Ltd

31

Q & A

==> picture [98 x 91] intentionally omitted <==

Please use the raise hand feature when asking questions and wait to be called on. We welcome all opinions.

==> picture [548 x 250] intentionally omitted <==

==> picture [64 x 65] intentionally omitted <==

<Please click this button to turn on the microphone

32

© 2021 SCP, Ltd

More from S.C.P.C

AGM Information 2026
May 19
Interim / Quarterly Report 2026
May 14
Regulatory Filings 2026
May 14
Interim / Quarterly Report 2026
May 13
Interim / Quarterly Report 2026
May 13
Regulatory Filings 2026
May 13
Regulatory Filings 2026
May 13
Interim / Quarterly Report 2026
May 13
Regulatory Filings 2026
May 12
Earnings Release 2026
May 12
View all filings →